The impact of HPV infection, smoking history, age and operability of the patient on disease-specific survival in a geographically defined cohort of patients with oropharyngeal squamous cell carcinoma

被引:15
作者
Ljokjel, Borghild [1 ]
Haave, Hilde [1 ]
Lybak, Stein [1 ,2 ]
Aarstad, Helene H. [2 ]
Karlsdottir, Asa [3 ]
Vintermyr, Olav K. [2 ,4 ]
Aarstad, Hans Jorgen [1 ,2 ]
机构
[1] Haukeland Hosp, Dept Otolaryngol Head & Neck Surg, N-5021 Bergen, Norway
[2] Univ Bergen, Fac Med & Dent, Dept Clin Med, N-5020 Bergen, Norway
[3] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway
[4] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway
关键词
Human papillomavirus; disease stage; age at diagnosis; head and neck squamous cell carcinoma; CAROTID-ARTERY INVASION; HUMAN-PAPILLOMAVIRUS; NECK-CANCER; SURGICAL-TREATMENT; HEAD; CHEMOTHERAPY; PREDICTION;
D O I
10.3109/00016489.2014.927590
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Conclusions: Patients with human papillomavirus (HPV)-positive tumours had better 5-year disease-specific survival (DSS) than HPV-negative patients. TNM score only predicted prognosis among HPV-negative patients. A previous history of smoking and age at diagnosis predicted DSS among HPV-positive patients whereas operability at diagnosis predicted DSS among both HPV-positive and HPV-negative patients. Objectives: HPV is a risk factor for oropharyngeal squamous cell carcinoma (OPSCC). The extent to which smoking, age and operability could play a role in HPV-positive surgically treated head and neck SCCs has not been extensively addressed previously and this study aimed to evaluate these factors. Methods: We identified 232 patients with OPSCC, of which 186 from the tonsil or base of the tongue region were treated in the period 1992-2008 in Western Norway. The 5-year DSS was recorded. Details on smoking history and whether the lesion was operable or not, as well as clinical information, were obtained retrospectively from the hospital records. Results: TNM stage predicted survival only among HPV-negative patients. A previous smoking affected prognosis only among HPV-positive patients (relative risk (RR) = 2.5; confidence interval (CI) = 1.0-6.2; p = 0.05). Increasing age of the patient had a negative effect on survival in HPV-positive patients only, especially among the oldest quartile (RR = 4.4; CI = 2.0-9.0; p < 0.001). Whether the tumour was operable or not uniquely predicted DSS both among HPV-positive (RR = 0.34; CI = 0.13-0.93; p < 0.05) and HPV-negative (RR = 0.25; CI = 0.10-0.66; p < 0.01) patients with tonsil/base of the tongue SCC.
引用
收藏
页码:964 / 973
页数:10
相关论文
共 15 条
  • [1] The impact of HPV infection on survival in a geographically defined cohort of oropharynx squamous cell carcinoma (OPSCC) patients in whom surgical treatment has been one main treatment
    Ljokjel, Borghild
    Lybak, Stein
    Haave, Hilde
    Olofsson, Jan
    Vintermyr, Olav K.
    Aarstad, Hans Jorgen
    ACTA OTO-LARYNGOLOGICA, 2014, 134 (06) : 636 - 645
  • [2] Association of Keratinization With 5-Year Disease-Specific Survival in Oropharyngeal Squamous Cell Carcinoma
    Cooper, Timothy
    Biron, Vincent L.
    Ben Adam
    Klimowicz, Alexander C.
    Puttagunta, Lakshmi
    Seikaly, Hadi
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2015, 141 (03) : 250 - 256
  • [3] Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy
    Vatca, M.
    Lucas, J. T., Jr.
    Laudadio, J.
    D'Agostino, R. B.
    Waltonen, J. D.
    Sullivan, C. A.
    Rouchard-Plasser, R.
    Matsangou, M.
    Browne, J. D.
    Greven, K. M.
    Porosnicu, M.
    ORAL ONCOLOGY, 2014, 50 (09) : 869 - 876
  • [4] Periodontal status at diagnosis predicts non-disease-specific survival in a geographically defined cohort of patients with oropharynx squamous cell carcinoma
    Farran, Mirna
    Loes, Sigbjorn Suk
    Vintermyr, Olav Karsten
    Lybak, Stein
    Aarstad, Hans Jorgen
    ACTA OTO-LARYNGOLOGICA, 2019, 139 (03) : 309 - 315
  • [5] In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality
    Kylma, Anna Kaisa
    Jouhi, Lauri
    Mohamed, Hesham
    Randen-Brady, Reija
    Makitie, Antti
    Atula, Timo
    Haglund, Caj
    Sorsa, Timo
    Hagstrom, Jaana
    ORAL ONCOLOGY, 2020, 107
  • [6] MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma
    Vento, Seija I.
    Jouhi, Lauri
    Mohamed, Hesham
    Haglund, Caj
    Makitie, Antti A.
    Atula, Timo
    Hagstrom, Jaana
    Makinen, Laura K.
    VIRCHOWS ARCHIV, 2018, 472 (06) : 975 - 981
  • [7] Females Have Worse Overall and Disease-Specific Survival in Human Papillomavirus-Negative Oropharyngeal Squamous Cell Carcinoma
    Hunter, William P.
    Harris, Jack A.
    Lee, Cameron C.
    Cheng, Allen C.
    Peacock, Zachary S.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2022, 80 (07) : 1260 - 1271
  • [8] Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation
    Broglie, Martina A.
    Soltermann, Alex
    Rohrbach, David
    Haile, Sarah R.
    Pawlita, Michael
    Studer, Gabriela
    Huber, Gerard F.
    Moch, Holger
    Stoeckli, Sandro J.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2013, 35 (12): : 1698 - 1706
  • [9] An oral cavity squamous cell carcinoma quantitative histomorphometric-based image classifier of nuclear morphology can risk stratify patients for disease-specific survival
    Lu, Cheng
    Lewis, James S., Jr.
    Dupont, William D.
    Plummer, W. Dale, Jr.
    Janowczyk, Andrew
    Madabhushi, Anant
    MODERN PATHOLOGY, 2017, 30 (12) : 1655 - 1665
  • [10] Nomogram-Based Prediction of Overall and Disease-Specific Survival in Patients With Postoperative Major Salivary Gland Squamous Cell Carcinoma
    Li, Lixi
    Zhang, Di
    Ma, Fei
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21